ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.514
-0.05%
Bitcoin
63,756.88
1.38%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) News

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
02/05/202420:30GlobeNewswire Inc.Regeneron Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/04/202421:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/04/202421:00GlobeNewswire Inc.Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/04/202400:05GlobeNewswire Inc.Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
23/04/202407:54GlobeNewswire Inc.Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/04/202421:18IH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/04/202421:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/04/202406:00GlobeNewswire Inc.Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/04/202407:05GlobeNewswire Inc.Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/03/202422:00GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for OdronextamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/202414:55PR Newswire (US)High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/202412:30GlobeNewswire Inc.High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/03/202422:00GlobeNewswire Inc.Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/202423:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/03/202408:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/03/202408:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/03/202408:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/02/202408:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/02/202408:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/02/202408:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202408:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202408:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202407:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/02/202408:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202417:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202409:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202408:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN

Your Recent History

ASX
XMM
S&P ASX 300 Metals and M...
ASX
XFL
S&P ASX 50
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
ASX
RIO
Rio Tinto
ASX
WBC
Westpac Banking
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
ASX
ANZ
Australia And New Zealan...
COIN
BTCUSD
Bitcoin
FTSE
UKX
FTSE 100
NASDAQ
AAPL
Apple
ASX
QBE
QBE Insurance
ASX
WOW
Woolworths
ASX
XTO
S&P ASX 100
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved